Over the past decade, artificial intelligence (AI) and automation have reshaped clinical research. From identifying drug ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical ...

Why future-ready pharma companies must embrace AI-driven, real-time decision-making. Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how AI is stepping in to fill staffing gaps in ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.

New data from the pivotal GEMZ study show significant seizure reduction with adjunctive fenfluramine in CDKL5 Deficiency ...

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how staffing reductions caused by clinical trial ...